Target intelligence / Profile preview

Patient-specific tumor-associated antigens presented on MHC (Patient-specific TAA-MHC)

Target
Patient-specific TAA-MHC
Molecular classification
Other
01

Overview

Patient-specific tumor-associated antigens presented on MHC (Major Histocompatibility Complex), commonly referred to as patient-specific neoantigens or tumor-specific antigens (TSAs) presented on MHC, represent a highly personalized class of therapeutic targets in oncology. These antigens arise from somatic mutations unique to an individual patient's tumor, such as single-nucleotide variants, frameshifts, or insertions/deletions, which are processed intracellularly and presented as short peptides on the cell surface by MHC class I or class II molecules. Because these neoantigens are absent in normal tissues, they are not subject to central immune tolerance, making them highly immunogenic and ideal targets for precision immunotherapy.

Therapeutic strategies targeting these patient-specific pMHC complexes include individualized neoantigen therapies (INTs), such as personalized mRNA- or peptide-based cancer vaccines (e.g., intismeran autogene and autogene cevumeran), as well as adoptive cell therapies like TCR-engineered T cells. Upon administration, these vaccines prompt antigen-presenting cells to display the selected neoantigens on their MHC molecules, priming and expanding a de novo repertoire of CD8+ cytotoxic T cells and CD4+ helper T cells. These activated T cells then selectively recognize and destroy tumor cells presenting the corresponding patient-specific antigens, minimizing off-target toxicities. However, the clinical efficacy of targeting these antigens can be limited by tumor-mediated downregulation of MHC expression, mutations in antigen-processing machinery, and the logistical challenges of rapid, patient-specific vaccine manufacturing.

Other names
Patient-specific tumor-associated antigens presented on major histocompatibility complexPatient-specific tumor neoantigens presented on MHCPatient-specific tumor-specific antigens presented on MHCPersonalized tumor neoantigens presented on MHCPatient-specific peptide-MHC complexesPatient-specific pMHCIndividualized tumor-associated antigens presented on MHC
02

Mechanism of action

Individualized neoantigen therapies or personalized cancer vaccines deliver genetic material or peptides encoding patient-specific neoantigens. These are taken up by antigen-presenting cells, processed, and presented on MHC class I and class II molecules. This presentation activates and expands patient-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, which then migrate to the tumor microenvironment, recognize the same neoantigens presented on the tumor cells' MHC, and selectively lyse the cancer cells.

03

Biological functions

Immune responseOther
04

Disease associations

Cancer
05

Safety considerations

Autoimmunity and off-target toxicityInjection site reactionsSystemic flu-like symptomsImmune-related adverse events when combined with checkpoint inhibitorsTumor immune evasion via MHC downregulationManufacturing failure or delays
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Tumor mutational burdenMicrosatellite instability-high statusHLA typingNeoantigen-specific T-cell responseMHC class I expressionMHC class II expression

Beyond the preview

Go deeper on Patient-specific tumor-associated antigens presented on MHC (Patient-specific TAA-MHC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Patient-specific tumor-associated antigens presented on MHC (Patient-specific TAA-MHC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call